The therapy, A2B543, will be added as an arm to the ongoing Phase I/II EVEREST-2 trial, which is testing CAR T-cell products developed using A2's Tmod platform. According to A2, the Tmod platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback